afuncan.com
Jan 7, 2025, 09:46
Glecirasib in KRASG12C-mutated non-small cell lung cancer by Yuankai Shi et al.
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a recent paper by Yuankai Shi, Professor of Oncology and Chief Physician at Cancer Hospital Chinese Academy of Medical Sciences, published in Nature Medicine:
“Glecirasib in KRASG12C-mutated non-small cell lung cancer: a phase 2b trial.
119 Chinese patients
Prior ICI used:94%
- ORR=47.9%
- PFS=8.2 months
- OS=13.6 months
G3-5 Adverse Effects – 60.5% (TRAE:38.7%, no G5).”
“Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial”
Authors: Yuankai Shi, Jian Fang, Ligang Xing, Qiao Li, Zhiyue Rao et al.
More posts featuring Yakup Ergün.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 13, 2025, 09:23
Feb 13, 2025, 09:17
Feb 13, 2025, 09:12
Feb 13, 2025, 09:10
Feb 13, 2025, 09:06
Feb 13, 2025, 08:58
Feb 13, 2025, 08:53
Feb 13, 2025, 08:52
Feb 13, 2025, 08:16